Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.57 |
| ▸ | XDH | P47989 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.48 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | CDK7 | P50613 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 3/20 | 0.39 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.39 |
| ▸ | MERTK | Q12866 | 4/20 | 0.38 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10779057 | 0.99 | POLA1 (0.56) | POLA1XDHCDK2PAK1ALDH1A1 | |
| SCHEMBL5934362 | 0.89 | POLA1 (0.54) | POLA1XDHCDK2PAK1ALDH1A1 | |
| SCHEMBL17099324 | 0.78 | XDH (0.43) | XDHCYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10779046 | 0.77 | XDH (0.44) | XDHDNM2KCNH3MERTKFLT3 | |
| SCHEMBL10922699 | 0.76 | POLA1 (0.45) | POLA1XDHCDK2PAK1ALDH1A1 | |
| SCHEMBL10995948 | 0.76 | POLA1 (0.45) | POLA1XDHCDK2PAK1ALDH1A1 | |
| SCHEMBL5196540 | 0.76 | XDH (0.52) | POLA1XDHCDK2PAK1ALDH1A1 | |
| SCHEMBL17099330 | 0.74 | XDH (0.55) | POLA1XDHCDK2CYP1A2CYP3A4 | |
| SCHEMBL9278629 | 0.74 | POLA1 (0.59) | POLA1XDHCDK2CYP1A2CYP3A4 | |
| SCHEMBL5072707 | 0.74 | CDK2 (0.58) | POLA1XDHCDK2PAK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115038702-A | Salt of arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2021147996-A1 | SALT OF ARYLAMINOPURINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-07-29 | — | — | WO | claimed |
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | claimed |
| US-9096601-B2 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2015-08-04 | — | — | US | claimed |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | SI Chuaan University (CN) | 2013-08-08 | — | — | US | claimed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | claimed |
| US-20240115575-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-04-11 | — | — | US | disclosed |
| CN-117777135-A | Deuterated arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777135-A | Deuterated arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117777135-A | Deuterated arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4272741-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-115038702-A | Salt of arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115038702-A | Salt of arylamino purine derivative and preparation method and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | disclosed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | disclosed |
| CN-103003278-A | Arylamino purine derivatives, preparation method and medical application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-103003278-A | Arylamino purine derivatives, preparation method and medical application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-103003278-A | Arylamino purine derivatives, preparation method and medical application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUANG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| WO-2011147066-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 四川大学 (CN) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147066-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 四川大学 (CN) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115575-A1 | PHARMACEUTICAL COMPOSITION OF MULTI-TARGET PROTEIN KINASE INHIBITORS, AND USE THEREOF | DMPK, PRKCB, PRKCA | POLA1 2837/4885XDH 3839/4885CDK2 132/4885 |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | EGFR, PNP, GART | POLA1 723/4885XDH 340/4885CDK2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.